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1. Introduction 
In gene therapy, the most important step is how to effectively deliver the therapeutic gene 
to the target cells or organ. At present, there are two methods, which are those using a 
viral and a non-viral vector system. The most common viral vectors that have been used 
include retroviruses, herpes simplex viruses, lentiviruses, adenoviruses and adeno-
associated viruses (Oligino et al., 2000). The advantages of most viral vectors are high 
transfection efficiency and fast transcription of the foreign material inserted in the viral 
genome. However, a number of disadvantages have also been described, such as poor 
target-specificity, low capacity to incorporate foreign deoxyribonucleic acid (DNA) 
sequence to their genome (Mansouri et al., 2004), toxic and inflammatory effects, wild–
type mutations, potential oncogenic effects (Lee et al., 1998), and, in particular, unwanted 
immune responses. In clinical trials of gene replacement therapy using viral vectors, 
significant adverse effects have been reported, including a fatal inflammatory response 
associated with adenoviral vector (Raper et al., 2003), and the development of acute 
leukaemia in recipients of ex-vivo, adenoviral vector-transduced hematopoietic cells 
(Woods et al., 2006). Intravenous adenoviral vector has also resulted in high liver toxicity 
due to uptake by hepatocytes or Kupffer cells of the liver reticular endothelial system, 
immediately following systemic administration. 
2. Non-viral vectors for gene delivery 
Due to the limitations and disadvantages of using viral vectors, there has been an ongoing 
search for an efficient safe vector for gene therapy, which has lead to the development of 
non-viral gene therapy. They have some advantages over viral methods, including simple 
large scale production and relatively low host immunogenicity. Previously, low levels of 
transfection and expression of the gene limited the usefulness of non-viral methods. 
However, recent advances in vector technology have been useful in yielding molecules and 
techniques with transfection efficiencies approaching or surpassing those of viral vectors.  
Table 1 provides examples of the main non-viral methods of gene delivery.  
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Non-viral method Examples 
Direct methods Injection of naked DNA 
Physical methods Electoporation 
 Gene gun 
 Sonoporation 
 Magnetofection 
Chemical methods Oligonucleotides 
 Lipoplexes and polyplexes 
 Dendrimers 
Table 1. Examples of non-viral methods of gene delivery 
Most non-viral vectors have no limitation in DNA size for packaging and they have the 
possibility of modification with ligands for tissue- or cell-specific targeting with low 
commercial cost and high reproducibility. Among these carriers, cationic lipids (lipoplexes) 
and cationic polymers (polycations) are primarily used, especially in in vitro gene 
transfection. Lipoplexes can form micelles or liposomes, which are multilayered structures, 
where the DNA is sandwiched between the cationic lipids. The lipoplexes present some 
problems due to their low physiological stability, reproducibility, and their toxicity of polar 
and hydrophobic moiety containing structure. In vivo, the intravenous administration of 
cationic lipid/DNA complexes presented significant problems, as these reagents can be 
quite toxic. On the other hand, polycations are more stable than lipoplexes and can protect 
DNA against nuclease degradation (Gao & Huang, 1996). Their structures also show more 
variability and versatility, including the possibility of incorporation of target-specific 
cellular receptors. Thus, modifications to these polymers, such as molecular weight (Mw), 
geometry (linear verses branched) and ligand attachment, can be easily undertaken 
successfully (Kim et al., 2007; Pack et al., 2005).  Furthermore, they can compact DNA 
molecules to a relatively small particle size. However, the efficiency of gene delivery by both 
complexes is still relatively low, when compared to viral vectors. Polyethylenimine (PEI) is a 
cationic polymer that has been used for non-viral gene transfection for some time, but due to 
its toxicity and the variable results, it has not been widely accepted. 
3. Chitosan as a non-viral carrier 
At present, chitosan is the most prominent of the non-viral carriers being investigated. The 
biomaterial, chitosan, has interested many researchers around the world, particularly in 
relation to its ability to be a gene delivery vehicle or the ability to modify this biopolymer for 
the gene delivery vehicle. This is because of its properties of biodegradability, 
biocompatibility, and low toxicity, and because it can be modified for increasing transfection 
efficiency, as well as for targeting gene delivery development. 
3.1 Molecular structure of chitosan 
Chitosan (poly[β-(1-4)-2-amino-2-deoxy-D-glucopyranose]) is a deacetylation product of 
chitin (see Figure 1), a high Mw natural polymer found in the shells of marine crustaceans, 
such as shrimps (see Figure 2), as well as various insects, the internal structures of other 
invertebrates, and in the cell walls of fungi. It also provides an avenue for recycling of 
marine shellfish waste, which can now be “mined” for chitin and chitosan (Hayes et  
al., 2008). 
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Fig. 1. Chemical structure of Chitin  
 
 
Fig. 2. Commercial chitosan is derived from the shells of shrimp and other sea crustaceans, 
including the Alaskan pink shrimp, pictured here (US National Oceanic and Atmosheric 
Administration, 2011) 
Deacetylation of chitin can be performed by boiling chitin from crab or shrimp shells in 
sodium hydroxide after decolourisation with potassium permanganate (Van Der Lubben et 
al., 2001). Chitosan is a co-polymer of glucosamine and N-acetyl-D-glucosamine. When the 
number of N-acetylglucosamine units exceeds 50%, the biopolymer is called chitin; the term 
‘chitosan’ is used to describe an N-acetyl-glucosamine unit content less than 50%. The 
chemical structure of chitosan is given in Figure 3. 
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Fig. 3. Chemical structure of chitosan. It is a linear polysaccharide composed of randomly 
distributed β-(1-4)-linked D-glucosamine (deacetylated unit) and N-acetyl-D-glucosamine 
(acetylated unit) 
3.2 Low toxicity of chitosan 
Chitosan has low toxicity with an LD50 (lethal dose for 50% of test population) level in the 
same dose as sugar or salt (Arai, 1968). Toxicity tests reported the LD50 of chitosan in mice 
exceeded 16 g/kg. The molecular mass has minimal effect on cell viability, while the degree of 
deacetylation (DDA) of the polymer has greater effect on its toxicity (Richardson et al., 1999). 
DDA also affects the solubility, hydrophobicity and its ability to interact electrostatically with 
polyanions by affecting the number of protonatable amine groups of chitosan. Chitosan 
nanoparticles with lower DDA showed lower toxicity in vitro (Huang et al., 2004). 
3.3 Applications of chitosan 
Chitosan is a biodegradable polymer used in various industrial, biomedical and 
pharmaceutical applications due to its biocompatibility and the slow release of active 
molecules. Table 2 summarizes some of these broader applications. The novel properties of 
chitosan make it a versatile biomaterial for cell therapy, tissue engineering and gene therapy 
(Sui et al., 2006). Chitosan has a positive charge and hydrophilic character at an acidic pH. It 
is a continuum of primary aliphatic amine that can be protonated by acids; the pKa of the 
chitosan amine groups being around 6.3-6.5 (Kumar et al., 2004). The cationic amino groups 
on the C2 position of the repeating glucopyranose units of chitosan can interact 
electrostatically with the anionic groups (usually carboxylic acid groups) of other polyions 
to form polyelectrolyte complexes (Hamman, 2010). Many different polyanions from a 
natural origin (e.g. alginate, chondrotin sulfate or dextran sulphate) or from a synthetic 
orgin [e.g. poly(acrylic acid), polyphosphoric acid, or poly(L-lactide)] have been used to 
form polyelectrolyte complexes with chitosan, in order to provide the required 
physicochemical properties for design of specific drug delivery system, as well as specific 
target gene delivery (J. H. Park et al., 2010). 
 
Usage Examples of applications 
Agricultural and horticultural Natural biocontrol and elicitor 
Water process engineering Part of filtration process 
Biomedical and pharmaceutical Hemostatic agents 
 Wound healing 
 Tissue engineering 
 Drug delivery 
 Gene therapy 
Table 2. Some applications of chitosan 
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4. Chitosan and gene delivery 
Chitosan has been broadly studied as a promising non-viral vector for gene delivery 
(Bowman & Leong, 2006). This cationic polysaccharide can bind DNA between the positive 
charges of its amino groups and the negative charges of the phosphate groups of the DNA 
backbone in order to form nano- or microparticles. The interaction between chitosan and 
nucleic acids is electrostatic. The charge interaction is sufficiently strong that chitosan-DNA 
or small interfering ribonucleic acid (SiRNA) complex does not dissociate until it has 
entered the cell. Moreover, chitosan also protected nucleic acids from enzymatic 
degradation before entering the nucleus.  
4.1 Transfection efficiency of chitosan 
Tong et al. (2009) describes seven steps that should be overcome before the expression of 
exogenous DNA. They are complexation, in vivo administration, endocytosis, escape from 
endolysosome, release of DNA, trafficking through cytoplasm and finally importation of 
DNA into the nucleus. The transfection efficiency of chitosan itself is; however, relatively 
low, when compared to lipoplex or other methods. But this aminopolysaccharide can be 
modified for ease of DNA delivery, as well as for target gene delivery, which currently 
attracts many researchers to use chitosan and its modifications for gene delivery. Chitosan 
can be modified by ligand conjugation, such as transferrin-, folate- (folate and transferrin are 
over expressed in cancer cells), mannose- (target dendritic cells in tumor) and galactose 
(target Kupffer cells of the liver) conjugated chitosan, which can improve transfection 
efficiency of the targeted cells via receptor–mediated endocytosis (Duceppe & Tabrizian, 
2010; Mao et al., 2010). 
4.2 Factors affecting transfection efficiency 
There are many factors that affect transfection efficiency. These include Mw, DDA, DNA 
complexes’ charge ratio, pH and particle sizes, as well as the type of cell lines used.  
4.2.1 Molecular weight (Mw) 
High Mw chitosan can bind DNA tightly, which is due to the high number of positive 
charge of amino groups, but binding DNA tightly may give low transfection efficiency, due 
to not releasing the DNA to the nucleus after endocytosis to the cell. The Mw of chitosan 
also influences the size of the chitosan–DNA complexes, as the higher sizes of chitosan-
DNA complexes can affect the cellular uptake. These factors lead to transfection efficiency 
(see review of Mao et al., 2010). 
If the N/P ratio, which is the molar ratio between the amino groups of chitosan and the 
phosphate groups of DNA, was fixed, then the higher the Mw , the larger the chitosan-DNA 
complexes diameter (MacLaughlin et al., 1998). However, there have been differing 
conclusions proffered between the Mw of chitosan and transfection efficiency. Some studies 
have reported of high transfection efficiency with high Mw chitosan (Huang et al., 2005; 
Kiang et al., 2004; MacLaughlin et al., 1998). Other studies have reported that low Mw 
chitosan has better transfection efficiency (Koping-Hoggard et al., 2004; Lavertu et al., 2006; 
Supaprutsakul et al., 2010).  
MacLaughlin et.al. (1998) synthesised depolymerised chitosan oligomers with a Mw from 7 - 
92, but the transfection efficiency was much lower than at the higher Mw of 102 and 230 
kDa, respectively, and being about 1000 times lower in transfection efficiency compared to 
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lipofectamineTM. Haung et al. (2005) also found a decreased A549 cellular uptake with the 
decreasing Mw or DDA of chitosan and a N/P ratio of 6 was used in that study. But the 
study of Supaprutsahul et al. (2010) revealed much higher transfection efficiency with the 
depolymerised chitosan at Mw ~16 kDa (or Mn ~ 6.5). This may be because of the different 
chitosan/DNA ratio, as the previous study used low N/P ratio, while Supaprutsakul et al. 
(2010) used chitosan/plasmid at an N/P ratio of about 56:1, which meant than a much 
higher amount of chitosan was used for the lower Mw. This was consistent with the study of 
Romøren et al. (2003), who found that low Mw chitosan was beneficial at the higher charge 
ratio of the complexes. 
4.2.2 pH and degree of deacetylation (DDA) 
The study of Lavertu et al. (2006) also found that the low Mw chitosan, which had a numeric 
average Mw (Mn) of about 10 and 80% DDA at N/P ratio 10:1, gave higher transfection 
efficiency at the same level as lipofectamineTM at pH 6.5. However, the very low Mw (1.9-7.7 
kDa) chitosans with high DDA were found to form aggregates easily, even at very low 
charge ratios (Morris et al., 2008), and this might lower the transfection. However, the 
depolymerised LW chitosan in this study had only 54% DDA, which may reduce the 
problem of particles aggregation and, after cells uptake the chitosan-DNA nanoparticles, the 
DNA may be released from the nanoparticles more easily, as DNA binding efficacy was 
reduced as DDA was decreased (Kiang et al., 2004). Hence, many factors may have to be 
considered for improving transfection efficiency of chitosan, not only the ligand binding, 
but also the method of binding or conjugation, the size and morphology of the particles, the 
aggregation of the complexes, and especially the chitosan itself, as Mw, DDA and charge 
ratio, which may have to be adjusted.  
4.2.3 Cell line dependency 
Another factor, which may affect transfection efficiency of chitosan, is cell line dependency. 
Higher mitotic cell lines, such as cancer cells, usually have higher transfection efficiencies that 
lower proliferative rates of the cell line. This may be related to differences in cell physiology 
affecting the internalisation mechanism and subsequent internal trafficking of the vectors 
(Douglas et al., 2008). It has also been found that dividing cells have higher transfection ability 
compared to quiescent cells (Brunner et al., 2000) and higher levels of gene expression have 
been observed just before or during mitosis (Mortimer et al., 1999).  This may explain why the 
immortalised cell line, with higher mitotic activity, has higher transfection ability than normal 
or primary cell lines. However, this factor requires further investigation. 
4.3 Improving transfection efficiency 
There have also some attempts to modify the chemical structure of chitosan to improve 
transfection efficiency, which have involved hydrophilic and hydrophobic modifications. 
The main purpose of hydrophilic modification of chitosan is to increase solubility and 
reduce sensitivity of chitosan-DNA complexes to pH, as well as reduce the chitosan-DNA 
complexes aggregation, which may improve transfection efficiency. The hydrophilic 
chitosan modification includes quaternised chitosan (Thanou et al., 2002), PEGylated 
(covalent attachment of polyethylene glycol polymer chains to another molecule) chitosan 
(Jiang et al., 2006) and low Mw soluble chitosan (Ercelen et al., 2006). Interestingly, Brannon-
Peppas & Blanchette (2004) found that particles with more hydrophobic surfaces were also 
preferentially taken up by the liver, followed by the spleen and the lungs. 
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Hydrophobic modifications of chitosan have been performed in many studies. The main 
objectives of these modifications were increasing transfection efficiency by modulating 
complex interactions with cells, especially in the complexes’ adsorption on the cell surfaces 
and cell uptake (Kurisawa et al., 2000). Some hydrophobic units also help in the dissociation 
between the chitosan DNA complexes to release DNA to enter the nucleus after cellular 
uptake, as well as protecting it from enzymatic degradation and facilitating intra cellular 
pDNA (plasmid DNA) association, which can enhance transfection efficiency. These 
hydrophobic modifications included deoxycholic chitosan, N-alkylated chitosan, thiolated 
chitosan and hybrid chitosan (Mao et al., 2010). The combination of hydrophilic and 
hydrophobic modification of chitosan structure has been another interesting area that looks 
highly promising for the development of high transfection efficiency in a non-viral vector, 
using chitosan as a core structure. 
5. Chitosan and gene therapy 
One of the significant applications of chitosan is in its application to gene therapy. It has a 
number of benefits. It has non-toxic, biodegradable and biocompatible with high cationic 
charge potential; protects DNA from degradation by nucleases; and has high yield 
transfection efficiency (Sui et al., 2006). Genetic material (DNA and RNA) has been explored 
for use as a treatment of genetic abnormalities or deficiencies, which is described as gene 
therapy. Gene therapy functions by transferring healthy genetic material or nucleic acid 
constructs, such as ribozymes, antisense molecules, decoy oligodeoxy nucleotides (ODNs), 
DNAzymes and siRNA, into diseased cells in an attempt to achieve a therapeutic effect that 
results in restoration of protein production, which was absent or deficient due to the pre-
existing genetic disorder (Tan et al., 2009). But using small nucleic acid, such as DNAzymes 
and siRNA, has some limitations, since they are rapidly degraded in plasma and cellular 
cytoplasm and cannot passively diffuse through cellular membrane, which is due to the 
strong anionic charge of the phosphate backbone and the consequent electrostatic repulsion 
from the anionic cell membrane surface as well as limited size of cellular entrance. So, these 
small nucleic acids encapsulated with chitosan nanoparticles can reduce the limitations of 
these small nucleic acids. 
5.1 Use of chitosan nanoparticles 
The development of chitosan and its modification for non-viral gene delivery is also a target 
for gene therapy. This is because chitosan nanoparticles have a low toxicity and are taken up 
by endosomes allowing the DNA or nucleic acid to overcome the permeability barrier posed 
by epithelium and also to protect against enzymatic degradation. There are some studies 
that have attempted to use chitosan for cancer therapy. Chitosan itself was able to 
demonstrate growth inhibitory effects on cancer cells and has apoptosis effect on bladder 
tumour cells via caspase-3 activation (Tan et al., 2009). The various manufacturing processes 
for chitosan nano-/micro- particles/spheres (nanofabrication) has been described elsewhere 
(Masotti et al., 2009). 
5.2 Use of siRNA loaded chitosan nanoparticles 
In current developments in chitosan for gene therapy, there is an attempt to develop siRNA 
loaded chitosan nanoparticles to silence the target gene. This method can silence the gene by 
means of RNA interfering (RNAi). SiRNAs, usually containing 20-25 base pairs (see Figure 
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4), assemble into endoribonuclease containing complexes known as RNA-induced silencing 
complexes (RISCs).  
 
 
Fig. 4. Schematic representation of a siRNA molecule. SiRNA have a well-defined structure: 
a short (usually 21-nucleotide-long) double-strand of RNA with 2-nucleotide 3’ overhangs 
on either end (Alper, 2006). 
The siRNA strands guide the RISCs to complementary RNA molecules leading to cleavage 
and destroy the target RNA (Manjunath & Dykxhoorn, 2010).  
The mechanism of RNAi is described in Figure 5.  
 
 
Fig. 5. Mechanism of RNAi (Hood, 2004). dsRNA=double stranded RNA; shRNA=small 
hairpin RNA (sequence of RNA that can be used to silence gene expression via RNA 
interference); mRNA=messenger RNA 
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This system is of interest to numerous researchers, as well as many pharmaceutical 
companies, since the efficient siRNA delivery system will have clinical therapeutic impact in 
gene therapy (Mao et al., 2010; Park et al., 2010; Rudzinski & Aminabhavi, 2010). However, 
further investigations are needed, especially in vivo experiments/clinical trials. 
6. Limitations in the use of chitosan 
There are some limitations in the use of chitosan for non-viral gene therapy. Firstly, there is 
a lack of knowledge of the pharmacokinetics of chitosan-nucleic acid complexes during 
uptake inside the body. When chitosan-DNA nanoparticles enter the body, they were 
quickly removed from the blood and deposited on different organs. Administration of larger 
nanoparticles results in a substantial increase of the particles in the lung with a subsequent 
decrease in the liver, indicating a strong dependence of the tissue distribution on particle 
size (Liu, 2007). However, more information on this topic is required. Secondly, there is a 
need for more studies in animals, including clinical trials.  
Most of the studies in the past few years about chitosan and gene therapy continue to use an 
in vitro model; however, more studies have been performed using mouse model, as 
summarised in Table 3. 
 
Route of 
transmission 
Form of chitosan 
complexes 
Target organ/
Disease 
Study design
 Reference 
Utero gene 
transfer 
(injection in 
amniotic sacs) 
Chitosan-DNA 
(reporter gene) 
Expected route 
for fetal gene 
therapy 
Mouse 
(murine) 
Yang et al., 
2008; Jang et 
al., in press 
Local gene 
delivery via 
endovascular 
stent 
Chitosan-DNA 
coated with 
dodecylated in 
endovascular 
stent 
Expected route 
for diseased 
blood vessel 
wall 
Mouse Zhu et al., 2010 
Local: 
inhalation 
Chitosan-DNA 
(interferon-beta 
gene) complexes 
powder 
Lung cancer Mouse Okamoto et al., 2010 
Local: 
inhalation 
Spray –freeze dry 
chitosan-DNA 
Expected route 
for pulmonary 
gene therapy 
Mouse Mohri et al., 2010 
Local: localized 
hydrogel by 
intra–tumoural 
injection 
Chitosan-SiRNA 
Expected route 
for multiple 
localized 
disease 
Mouse models 
of melanoma 
and breast 
cancers 
Han et al., 
2010 
Local: intra-
tumoural 
injection 
Chitosan-SiRNA 
design to down 
regulate RXFP1 
expression 
Prostate 
cancer 
Mouse: 
xenograft 
model 
Feng et al., 
2010 
Table 3. Summary of current animal experiments using chitosan as non-viral for gene 
therapy 
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Lastly, the route of transmission and target gene delivery are the major factors which 
contribute to the success in gene therapy, which still requires further investigation.  
Table 4 summarises some attempts to modify the chitosan-nucleic acid complexes for target 
gene therapy. 
 
Modification Chitosan complexes Conclusion Study design Reference 
Folate mediated 
targeting induced 
by conjugating 
poly(ethylene 
glycol)-folate 
(PEG-FA) with 
arginine modified 
chitosan 
PEG-FA-
chitosan-DNA 
The transfection 
efficiency was 
higher than PEI 
when transfected in 
KB cell line, which 
over expressed the 
folate receptor (FR) 
in presence of 10% 
foetal bovine serum 
(FBS). 
In vitro  
(KB cell line) 
Morris & 
Sharma, 
2010 
Arg-Gly-Asp 
(RGD) peptide-
labelled chitosan 
nanoparticle 
(RGD-CH-NP) as 
a novel tumour 
targeted delivery 
system for short 
interfering RNA 
(siRNA). 
RGD-CH—
SiRNA 
nanoparticles 
RGD-CH-NP is a 
novel and highly 
selective delivery 
system for siRNA 
with the potential 
for broad 
applications in 
human disease. 
Orthotopic 
mouse 
models of 
ovarian 
carcinoma 
Han et al., 
2010 
Antisense oligo-
deoxynucleotides 
(asODN), using 
folic acid (FA) 
conjugated 
hydroxypropyl-
chitosan 
FA-Chtosan-
asODN 
nanoparticles 
Targeted antisense 
agent would be a 
potential approach 
to overcome 
tumour drug 
resistance. 
In vitro  
(KB cell line) 
Wang et 
al., 2010 
Tumour- of 
adenoviral 
complexes  
targeting of 
Adenovirus 
(Ad)/chitosan-
PEG-FA 
nanocomplexes 
formed by 
electrospining 
Ad/chitosan-
PEG-FA nano-
complexes 
Transduction 
efficiency of 
Ad/chitosan-PEG-
FA was 57% higher 
than Ad/chitosan. 
This system aims 
for development of 
systemic 
administration of 
the vectors to target 
lesion. 
In vitro  
(KB cell line) 
Park et al., 
2010 
Table 4. Some modifications of chitosan for target gene therapy 
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7. Summary 
An efficient gene delivery system is very important for gene therapy. Currently, the most 
efficient of these systems is a viral vector, which usually yields a transfection efficiency of 
more than 90%. However, by using a viral vector for gene therapy, there is a concern about 
the host versus vector immunological response, mutation and oncogenic effects; hence the 
need to develop a non-viral vector. There are many non-viral vectors; the high efficient one 
is cationic lipid, which gives high transfection efficiency, especially in tissue culture or in 
vitro conditions. In vivo, the intravenous administration of cationic lipid/DNA complexes 
presented significant problems, as these reagents can be quite toxic. PEI is another non-viral 
transfection material that has been used for some time, but due to its toxicity and the 
variable results, it has not been widely accepted. 
Chitosan (poly[β-(1-4)-2-amino-2deoxy-D-glucopyranose]), a nontoxic biodegradable 
biopolymer, has been broadly studied as a promising non-viral vector for gene delivery. 
This cationic polysaccharide has been produced by partial deacetylation of chitin, a 
naturally polymer from crustacean shells. However, the transfection efficiency of chitosan 
itself is not efficient enough and depends on many factors such as Mw, DDA, DNA 
complexes charge ratio, pH and particle sizes, as well as the type of cells. There have been 
many attempts to modify chitosan in order to improve transfection efficiency. Some 
studies have revealed that low Mw chitosan, especially the product of oxidative 
depolymerisation from higher Mw chitosan with NaNO2, had low cytotoxicity and 
improved solubility properties, as well as having potential for gene delivery both in vitro 
and in vivo. However, some studies have reported decreased transfection efficiency with 
lower Mw chitosan.  
There have been other attempts modifying the chemical structure of chitosan. These have 
included introducing a hydrophilic group, such as coupling dextran, as well as 
incorporating poly (vinyl pyrolidone) into the galactosylated chitosan, which can reduce 
the aggregation of particles and increase transfection efficiency. Some studies have also 
using hydrophobic modification of chitosan, such as deoxycholic acid-modified chitosan, 
in order to increase transfection efficiency through enhancement of complex interaction 
with cells and cellular uptake of the particles. Chitosan can be modified by conjugation of 
chitosan-DNA complexes with ligands to target specific cell surface receptors, but these 
attempts have had variable results. Many factors may have to be considered for 
improving transfection efficiency of chitosan, not just ligand binding, but also the method 
of binding or conjugation, the size and morphology of the particles, the aggregation of the 
complexes, and especially the chitosan itself, as Mw, DDA and charge ratio may have to 
be adjusted. 
The design criteria of the effective vector for non-viral gene therapy should also consider 
cost–effectiveness in synthesis and purification steps, serum stability and efficient 
packaging of large amount of the vector-nucleic acid complexes. Moreover, the route of 
administration of this vector to the target cells or tumour lesion, high transfection 
efficiency, specific target gene delivery should also be considered. Once the complexes 
enter the target cells, they have to escape from enzyme degradation. The complexes then 
release the therapeutic gene/ nucleic acid to the target organelle, such as DNA, which has 
to enter the nucleus, while siRNA functions in cytoplasm. This release has to occur 
without too many difficulties, which means that the bonding between the vectors and 
nucleic acid should not be too strong. Most importantly, these non-viral vectors have to be 
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safe enough for the patient, including being non toxic to the host body, non-immunogenic 
and non pathogenic. Chitosan is now one of the candidate biomaterials for selection as an 
effective non-viral vector for gene therapy, especially as it is safe, cheap and easy to 
modify. 
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